Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > If TH1902 does not work, we are done..YES or NO?

<< Previous

Bullboard Posts

Next >>

Comment by Lee430on Aug 08, 2022 3:04pm

107 Views

Post# 34879580

RE:If TH1902 does not work, we are done..YES or NO?

For my situation if the TH1902 trial fails I will have no choice but to exit ASAP

TH1902 wrote: What do you all think?

Patiently here for years and feel like I've been strung along with promise after promise from this company.

I think if the Oncology program flops, its over...thoughts and opinions?

I would maybe prefer a partnership sooner than later to offset risk going forward...biotechs are hard...